Ricardo Innovative Climate-Repairing Carbon Negative Technology to Support National Energy Security
12.7.2022 02:01:00 EEST | Business Wire | Press release
As part of its mission to support the decarbonisation of the global energy sector, Ricardo, a world-class, strategic environmental and engineering consulting company, has received 3million GBP from the UK Government to design, install and operate a combined heat and power demonstrator plant with a carbon negative footprint which will showcase climate repairing technology. The plant will demonstrate the effectiveness of community scale greenhouse gas removal and clean energy using sustainably-sourced forestry waste. The funding is awarded through the Net Zero Innovation Portfolio (NZIP) under the Department of Business, Energy and Industrial Strategy (BEIS).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220711005348/en/
Homested Farm carbon capture demonstrator site (Photo: Business Wire)
Ricardo is leading the consortium delivering the demonstrator plant. The consortium combines an innovative carbon capture system developed by Ricardo with the hot air turbine technology from Bluebox Energy and pyrolysis technology from Woodtek Engineering. The quarter-sized demonstrator plant, which will be located at Holmsted Farm in West Sussex in the UK, will be commissioned and operational in 2023. It will demonstrate not only a highly innovative greenhouse gas removal technology, that in the full-size system can generate renewable heat and electricity for up to 300 local homes and businesses, but also a realistic carbon negative technology that can significantly contribute to net zero targets.
Tim Curtis, Managing Director, Ricardo Energy and Environment said: “Ricardo is a trusted advisor to governments around the world on climate change policy and the transition to clean energy, and is also well known for its mission to decarbonise the global transport and energy sectors. In partnership with Bluebox Energy and Woodtek Engineering, this project will demonstrate that our innovative and integrated carbon capture system can be used to benefit local communities, bolster the UK’s reputation as a pioneer in negative emission technologies, and provide a sustainable and commercially viable pathway to net-zero while also delivering national energy security.”
Ricardo’s project is one of several across the UK which will benefit from a share of over 54 million GBP to develop technologies that remove carbon emissions from the atmosphere. Announcing this investment, UK Government’s Energy and Climate Change Minister Greg Hands said: “This 54 million GBP government investment will help establish a greenhouse gas removal industry in the UK, which could be worth billions to our economy, bringing in private investment and supporting the creation of new green jobs.”
The technology works by taking sustainably sourced waste wood from domestic timber production and then processing it in three ways: producing biochar (a product similar to charcoal); generating heat and power; and capturing carbon dioxide from the exhaust. The technology, therefore, captures around 95% of the carbon content in the wood. It also produces commercially marketable carbon products: the biochar can be used by farmers to enrich soil and add to animal feed to reduce ruminant emissions. The industrial-grade carbon dioxide can either be used for making low-carbon concrete or in the food and drinks industry to replace carbon dioxide derived from industrial processes which rely on imported natural gas. A full-size system will remove 16,000 tonnes of carbon dioxide per year from the atmosphere.
Ricardo has been collaborating with Bluebox Energy since June 2020 to deliver innovative technologies that support the transition to a low carbon future. This project is a further boost to Ricardo’s credentials in tackling climate change and meeting national net zero targets. Ricardo is currently actively supporting clients in Europe in innovative carbon capture technologies and has advised the UK Government on the potential of bioenergy with carbon capture in the UK. Ricardo supports clients across a wide range of industries develop their industrial decarbonisation plans on the route to net zero.
Ends
About Ricardo
Ricardo plc is a world-class strategic, environmental, and engineering consulting company, listed on the London Stock Exchange. With over 100 years of engineering excellence and employing close to 3,000 employees in more than 20 countries, we provide exceptional levels of expertise in delivering leading-edge and innovative cross-sector sustainable products and solutions. Every day, we enable our customers to solve the most complex and dynamic challenges to help achieve a safe and sustainable world. Visit www.ricardo.com
Department for Business, Energy & Industrial Strategy
This funding has been made available from the government’s £1 billion Net Zero Innovation Portfolio, which looks to accelerate the commercialisation of low-carbon technologies and systems, through its Direct Air Capture and Greenhouse Gas Removal Innovation Competition. This competition will provide funding for developing technologies that enable the removal of greenhouse gases from the atmosphere in the UK.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220711005348/en/
Contact information
Media contacts:
Kathryn Bellamy
Group Senior Communications Manager
Ricardo plc
Email: kathryn.bellamy@ricardo.com
Telephone: +44(0)7921 941824
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
